Vaccine discovery and translation of new vaccine technology

The Lancet

Volumn 378, Issue 9788, 2011, Pages 360-368

  Rappuoli, Rino ^a   Black, Steven ^b   Lambert, Paul Henri ^c  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER VACCINE; CHOLERA VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA POLIOMYELITIS TETANUS VACCINE; DNA VACCINE; GLYCOPROTEIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HELICOBACTER PYLORI VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LEISHMANIA VACCINE; MALARIA VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; PNEUMOCOCCUS VACCINE; RABIES VACCINE; RNA VACCINE; SMALLPOX VACCINE;

AGING; AUTOIMMUNE DISEASE; AWARENESS; BACTERIAL COLONIZATION; BIOETHICS; CANCER IMMUNOTHERAPY; CLONAL ANERGY; DEVELOPING COUNTRY; DIPHTHERIA; DISEASE SURVEILLANCE; DISSEMINATED VACCINIA; DRUG COST; DRUG FATALITY; DRUG MARKETING; DRUG MEGADOSE; DRUG PURITY; DRUG SAFETY; ENCEPHALITIS; FEBRILE CONVULSION; GENETIC RISK; GUILLAIN BARRE SYNDROME; HELICOBACTER INFECTION; HUMAN; IMMUNOGENICITY; INFECTION; INFLUENZA A (H1N1); INNATE IMMUNITY; LEISHMANIASIS; LICENSING; LOW DRUG DOSE; MALARIA; MYOCARDITIS; NEOPLASM; NONHUMAN; PANDEMIC INFLUENZA; PARALYSIS; PARALYTIC POLIOMYELITIS; POLIOMYELITIS; PREGNANT WOMAN; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RABIES; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SMALLPOX; STREPTOCOCCUS PNEUMONIA; TETANUS; TREATMENT INDICATION; TREATMENT RESPONSE; TUBERCULOSIS; VACCINATION; VACCINE PRODUCTION; VACCINIA; VIRUS ENTRY; VIRUS LIKE AGENT;

EID: 79960712314     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60440-6     Document Type: Review

References (61)

1. F Fenner A successful eradication campaign. Global eradication of smallpox Rev Infect Dis 4 1982 916 930
2. Immunization Action Coalition Historic dates and events related to vaccines and immunization http://www.immunize.org (accessed Oct 15, 2010).
3. S Plotkin, W Orenstein, P Offit Vaccines 5th edn. 2008 Saunders Elsevier Philidelphia, PA 1 12
4. AM Galazka, SE Robertson Immunization against diphtheria with special emphasis on immunization of adults Vaccine 14 1996 845 857 (Pubitemid 26280925)
5. P Offit The Cutter incident: how America's first polio vaccine led to the growing vaccine crisis 2005 Yale University Press New Haven, CT
6. JF Bell, JT Wright, K Habel Rabies vaccine freed of the factor causing allergic encephalitis Proc Soc Exp Biol Med 70 1949 457 461
7. LN Alexander, JF Seward, TA Santibanez et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States JAMA 292 2004 1696 1701 (Pubitemid 39346671)
8. CE Stevens, PE Taylor, MJ Tong et al. Yeast-recombinant hepatitis b vaccine JAMA 257 1987 2612 2616
9. S Black, HR Shinefield, RA Hiatt, BH Fireman Efficacy of Haemophilus influenzae type b capsular polysaccharide vaccine Pediatr Infect Dis J 7 1988 149 155
10. N MacDonald, SA Halperin, BJ Law et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers JAMA 280 1998 1685 1689 (Pubitemid 28532992)
11. J Wenger Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada Pediatr Infect Dis J 17 1998 132 136
12. SL Kaplan, EO Mason, ER Wald et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine Pediatrics 113 2004 443 449 (Pubitemid 38280781)
13. P Balmer, R Borrow, E Miller Impact of meningococcal C conjugate vaccine in the UK J Med Microbiol 51 2002 717 722
14. BR Kirkwood, S Gove, S Rogers, J Lob-Levyt, P Arthur, H Campbell Potential interventions for the prevention of childhood pneumonia in developing countries: a systematic review Bull World Health Organ 73 1995 793 798
15. S Rosenthal, R Chen, S Hadler The safety of acellular pertussis vaccine versus whole cell pertussis vaccine Arch Pediatr Adolesc Med 150 1996 457 460 (Pubitemid 126515534)
16. JA Tree, C Richardson, A Fooks, JC Clegg, D Looby Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains Vaccine 19 2001 3444 3450 (Pubitemid 32710294)
17. A Podda, G del Giudice MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile Expert Rev Vaccine 2 2003 197 204 (Pubitemid 36559925)
18. D Descamps, K Hardt, B Spiessens et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials Human Vaccinol 5 2009 332 340
19. FA Wyle, MS Artenstein, BL Brandt et al. Immunologic response of man to group b meningococcal polysaccharide vaccines J Infect Dis 126 1972 514 522
20. R Rappuoli Reverse vaccinology, a genome-based approach to vaccine development Vaccine 19 2001 2688 2691 (Pubitemid 32234290)
21. D Serruto, R Rappuoli Post-genomic vaccine development FEBS Lett 580 2006 2985 2992 (Pubitemid 43729171)
22. TA Bowden, M Crispin, EY Jones, DI Stuart Shared paramyxoviral glycoprotein architecture is adapted for diverse attachment strategies Biochem Soc Trans 38 2010 1349 1355
23. F Zepp Principles of vaccine design - lessons from nature Vaccine 28 suppl 3 2010 14 24
24. PW Kantoff, TJ Schuetz, BA Blumenstein et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA taregeted immunotherapy in metastatic castration resistant prostate cancer J Clin Oncol 28 2010 1099 1105
25. S Black, HR Shinefield, E Lewis et al. Safety, efficacy, immunogenicity of heptavalent pneumococcal conjugate in children Pediatr Infect Dis J 19 2000 187 195 (Pubitemid 30167436)
26. H Kitano Systems biology: a brief overview Science 295 2002 1662 1664 (Pubitemid 34202893)
27. IA Ramshaw, AJ Ramsay The prime-boost strategy: exciting prospects for improved vaccination Immunol Today 21 2000 163 165 (Pubitemid 30184783)
28. G Pialoux, JL Excler, Y Rivire et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA AIDS Res Hum Retroviruses 11 1995 875
29. A Bringmann, SA Held, A Heine, P Brossart RNA vaccines in cancer treatment J Biomed Biotechnol 2010 10.1155/2010/623687 published online June 1.
30. G Galli, D Medini, E Borgogni et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels Proc Natl Acad Sci USA 10 2009 3877 3882
31. W Zhu, BW Higgs, C Morehouse et al. A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children Vaccine 28 2010 2865 2876
32. T Ray, C Whitney, BH Fireman, V Ciuryla, SB Black Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effect Pediatr Infect Dis J 25 2006 494 501 (Pubitemid 43863358)
33. ML Halliday, JG Rankin, NJ Bristow, RA Coates, PNJ Corey, AC Strickler A randomized double-blind clinical trial of a mammalian cell-derived recombinant DNA hepatitis b vaccine compared with a plasma-derived vaccine Arch Intern Med 150 1990 1195 1200 (Pubitemid 20188452)
34. M Gréco, L Hessel Development and supply of vaccines: an industry perspective M Levine G Dougan MF Good New generation vaccines 4th edn. 2009 Informa Healthcare London
35. AL Bisno Group A streptococcal infections and acute rheumatic fever N Engl J Med 325 1991 783 793
36. DC Wraith, M Goldman, PH Lambert Vaccination and autoimmune disease: what is the evidence? Lancet 362 2003 1659 1666 (Pubitemid 37443537)
37. J Nedelec, J Boucraut, JM Garnier, D Bernard, G Rougon Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis J Neuroimmunol 29 1990 49 56 (Pubitemid 20283781)
38. F Mosca, E Tritto, A Muzzi et al. Molecular and cellular signatures of human vaccine adjuvants Proc Natl Acad Sci USA 105 2008 10501 10506
39. AM Didierlaurent, S Morel, L Lockman et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity J Immunol 183 2009 6186 6197
40. AT Kamath, AF Rochat, D Christensen et al. A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells PLoS One 4 2009 e5771
41. O Zhang, L Bagrade, E Clarke, JC Paton, DA Nunez, A Finn Bacterial lipoproteins differentially regulate human primary and memory CD4+ T and B Cell responses to pneumococcal protein antigens through toll-like receptor 2 J Infect Dis 201 2010 1753 1763
42. VA Fulginiti, A Papier, JM Lane, JM Neff, DA Henderson Smallpox vaccination: a review, part II. Adverse events Clin Infect Dis 37 2003 251 271 (Pubitemid 36930357)
43. M Gilchrist, V Thorsson, B Li Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor Nature 441 2006 173 178
44. RT Chen, JW Glasser, PH Rhodes et al. Vaccine safety datalink project: a new tool for improving vaccine safety monitoring in the United States Pediatrics 99 1997 765 773 (Pubitemid 27231345)
45. P Farrington, M Rush, E Miller et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines Lancet 345 1995 567 569
46. NP Klein, B Fireman, K Yih et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures Pediatrics 126 2010 1 8
47. LL Su, J Chan, YS Chong, M Choolani, A Biswas, EL Yong Pregnancy and H1N1 infection Lancet 374 2009 1417 1418
48. Centers for Disease Control and Prevention Preliminary results: surveillance for Guillain-Barré syndrome after receipt of Influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010 http://www.cdc.gov/ mmwr/preview/mmwrhtml/mm5921a3.htm (accessed May 5, 2011).
49. TW Clark, M Pareek, K Hoschler et al. Trial of influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine - preliminary report N Engl J Med 361 2009 1 11
50. T Tsai, MH Kyaw, D Novicki, P Nacci, S Rai, R Clemens Exposure to MF59-adjuvanted influenza vaccines during pregnancy - a retrospective analysis Vaccine 28 2010 1877 1880
51. Centers for Disease Control and Prevention Active bacterial core surveillance http://www.cdc.gov/abcs/reports-findings/surv-reports.html (accessed May 5, 2011).
52. HE Hsu, KA Shutt, MR Moore et al. Impact of pneumococcal conjugate vaccine on pneumococcal meningitis in the United States, 1998-2005 N Engl J Med 360 2009 244 256
53. W Hausdorff, J Bryant, PR Paradiso, GR Siber Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I Clin Infect Dis 30 2000 100 121 (Pubitemid 30067069)
54. S Madhi, P Adrian, L Kuwanda, C Cutland, W Albrich, K Klugman Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumonia and associated interactions with Staphylococcus aureus and Haemophilus influenza colonization in HIV-infected and HIV-uninfected children J Infect Dis 196 2007 1662 1666 (Pubitemid 351411964)
55. ER Moxon, C-A Siegrist The next decade of vaccines: societal and scientific challenges Lancet 2011 10.1016/S0140-6736(11)60407-8 published online June 9.
56. R Urwin, MCJ Maiden Multi-locus sequence typing: a tool for global epidemiology Trends Microbiol 11 2003 479 487 (Pubitemid 37214875)
57. JL Goodman Meeting the challenge of pandemic vaccine preparedness: FDA perspectives https://www.who.int/vaccine-research/diseases/influenza/ Goodman20(2).pdf (accessed May 5, 2011).
58. Centers for Disease Control and Prevention CDC immunization schedules http://www.cdc.gov/vaccines/recs/schedules/ (accessed May 5, 2011).
59. L Roberts Costs of meningitis outbreaks are crippling too Science 320 2008 1712
60. Centers for Disease Control and Prevention 2011 child & adolescent immunization schedules http://www.cdc.gov/vaccines/recs/schedules/child- schedule.htm (accessed May 5, 2011).
61. P Burch, GA Croghan, DA Gastineau et al. Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial Prostate 60 1994 197 204